

U.S.S.N. 09/966,545  
 Filed: September 26, 2001

Rule  
 126

B5

- 20<sup>18</sup> 74. (Amended) The nucleic acid of claim 72, wherein said nucleic acid comprises an open reading frame that encodes a polypeptide of SEQ ID NO: [22] 16 or its complement, or a mutant or variant thereof.

B6

- 21<sup>18</sup> 75. (Amended) The nucleic acid of claim 72, wherein said nucleic acid encodes a polypeptide comprising an amino acid of SEQ ID NO: [22] 16 or its complement.

B7

- 22<sup>20</sup> 76. (Amended) The nucleic acid of claim 74 wherein the nucleic acid encodes a mature form of a polypeptide comprising an amino acid sequence that is SEQ ID NO: [22] 16.

B8

- 23<sup>21</sup> 77. (Amended) The nucleic acid of claim 75 wherein said nucleic acid encodes a polypeptide comprising an amino acid of SEQ ID NO: [22] 16, a mutant or variant thereof.

B9

- 24<sup>18</sup> 78. An oligonucleotide sequence that is complimentary to and hybridizes under stringent conditions with the nucleic acid of claim 72, a variant or mutant thereof.

B10

- 25<sup>24</sup> 79. (Amended) The oligonucleotide sequence of claim 78 which is complementary to at least a portion of the nucleotide sequence of SEQ ID NO: [21] 15, its complement, or a mutant or variant thereof.

B11

- 26<sup>20</sup> 80. An isolated nucleic acid comprising a nucleotide sequence complementary to at least a portion of a nucleic acid according to claim 74.

B12

- 27<sup>18</sup> 81. A vector comprising the nucleic acid of claim 72.

B13

- 28<sup>27</sup> 82. A cell comprising the vector of claim 81.

B14

- 29<sup>28</sup> 83. (Amended) The cell of claim 82 wherein said cell is a prokaryotic or eukaryotic cell comprising the nucleic acid sequence which is SEQ ID NO: [21] 15, its complement, or a mutant or variant thereof.

B15 30  
84. A pharmaceutical composition comprising the nucleic acid of claim ~~72~~<sup>18</sup> and a pharmaceutically acceptable carrier.

B16 31  
85. (Amended) A process for producing a polypeptide encoded by the nucleic acid of claim ~~72~~<sup>18</sup>, said process comprising:  
a) providing [the] a cell comprising a vector comprising the nucleic acid of claim [82]  
~~18~~<sup>18</sup> ~~72~~;  
b) culturing said cell under conditions sufficient to express said polypeptide; and  
c) recovering said polypeptide,  
thereby producing said polypeptide.

B17 32  
86. The process of claim ~~85~~<sup>31</sup> wherein said cell is a prokaryotic or eukaryotic cell.

33  
87. A process for identifying a compound that binds the nucleic acid of claim ~~72~~<sup>18</sup>, the process comprising:  
a) contacting said nucleic acid with a compound; and  
b) determining whether said compound binds said nucleic acid sequence.

B18  
B19 34  
88. The compound identified by the process of claim ~~87~~<sup>33</sup>.

*Pursuant to 37 CFR §1.121(c), a clean version of the claims is attached as pages 94-95 in the substitute specification.*

#### REMARKS

Upon entry of the above amendments, claims 72-88 will be pending. Amendments to the title, claims 72, 74-77, 79 and 83 and to the abstract on page 96 are supported at least, *e.g.*, in the specification as originally filed at page 14, lines 4-19. Claims 85 was amended to remove multiple dependency, and is supported by claims 81 and 82 as filed.